US Patent

US7932241 — Pharmaceutical products comprising bisphosphonates

Formulation · Assigned to Novartis AG · Expires 2028-02-05 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical product that is a ready-to-use infusion solution of a bisphosphonate in a heat-sterilizable container made of plastic.

USPTO Abstract

A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

Drugs covered by this patent

Patent Metadata

Patent number
US7932241
Jurisdiction
US
Classification
Formulation
Expires
2028-02-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.